...Single-dose Cohort in Phase 1 Clinical Trial of PMC-403...
a clinical-stage public company developing next-generation therapeutics to address unmet medical needs, today announced that its TIE2-activating antibody candidate,PMC-403, has received unanimous safety approval from the Sa...